Recurrent Digital Petechiae and Weight Loss in a Young Adult

Aventín, Daniel López; Ilzarbe, Lucas; Herrero-González, Josep E.

doi:10.1053/j.gastro.2013.03.007

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In combination with a NA, GS-9620 appears to increase T-cell and natural killer cell responses and to reduce the ability of natural killer cells to suppress T cells in chronic hepatitis B patients, raising the possibility that GS-9620 might potentially be used as an adjunct drug in HBV treatment to augment the immune response to HBV ( Boni et al, 2018 ). However, comparing the data from chimpanzees and woodchuck models ( Lanford et al, 2013 ; Menne et al, 2015 ), a much lower efficacy of GS-9620 in clinical trials in humans has been reported, since no significant effect was shown on serum HBsAg levels, tempering the previous expectation ( Agarwal et al, 2018 ; Boni et al, 2018 ). The reason for this finding might be that the animals received higher doses (in terms of concentration and/or frequency) than those used in CHB patients.…”

Section: Rational For Ifn-based Treatment Of Chronic Hepatitis Bmentioning

confidence: 97%

“…GS-9620, a toll-like receptor 7 agonist, which was first evaluated in HBV-infected chimpanzees in 2013 ( Lanford et al, 2013 ), has demonstrated a prolonged inhibition of HBV replication via a type I IFN-dependent mechanism ( Niu et al, 2017 ). In combination with a NA, GS-9620 appears to increase T-cell and natural killer cell responses and to reduce the ability of natural killer cells to suppress T cells in chronic hepatitis B patients, raising the possibility that GS-9620 might potentially be used as an adjunct drug in HBV treatment to augment the immune response to HBV ( Boni et al, 2018 ).…”

Section: Rational For Ifn-based Treatment Of Chronic Hepatitis Bmentioning

confidence: 99%

See 1 more Smart Citation

When Hepatitis B Virus Meets Interferons

Tan

Song

et al. 2018

Front. Microbiol.

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection imposes a severe burden on global public health. Currently, there are no curative therapies for millions of chronic HBV-infected patients (Lok et al., 2017). Interferon (IFN; including pegylated IFN) is an approved anti-HBV drug that not only exerts direct antiviral activity, but also augments immunity against HBV infection. Through a systematic review of the literature, here we summarize and present recent progress in research regarding the interactions between IFN and HBV as well as dissect the antiviral mechanisms of IFN. We focus on inhibition of HBV replication by IFN-stimulated genes (ISGs) as well as inhibition of IFN signaling by HBV and viral proteins. Finally, we briefly discuss current IFN-based HBV treatment strategies. This review may help to better understand the mechanisms involved in the therapeutic action of IFN as well as the crosstalk between IFN and HBV, and facilitate the development of both direct-acting and immunology-based new HBV drugs.

show abstract

Section: Rational For Ifn-based Treatment Of Chronic Hepatitis Bmentioning

confidence: 97%

Section: Rational For Ifn-based Treatment Of Chronic Hepatitis Bmentioning

confidence: 99%

When Hepatitis B Virus Meets Interferons

Tan

Song

et al. 2018

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Acral purpurae and petechiae are a common cutaneous finding among DH patients and may even represent the initial manifestation of the disease 27,34–38 . Haemorrhagic skin lesions affect mostly the fingers and the toes (digital purpura).…”

Section: Diagnosticsmentioning

confidence: 99%

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Görög

Antiga

Caproni

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten‐induced skin disorder characterized by subepidermal granular IgA deposition and a variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management of DH. Methods The guidelines were created by small subgroups of a guideline committee consisting of 26 specialists from various medical fields and one patients’ representative. The members of the committee then discussed the guidelines and voted for the final version at two consensus meetings. The guidelines were developed under the support of the European Academy of Dermatology and Venereology (EADV) and in collaboration with the European Dermatology Forum (EDF). Results The guidelines summarize evidence‐based and expert‐based recommendations (S2 level) for the management of DH (see Appendix). Conclusion These guidelines will improve the quality of management of DH and support dermatologists in their diagnostic and therapeutic decisions.

show abstract

“…Acral purpura and petechiae are a common finding among DH patients and may even indicate an early-stage disease: these hemorrhagic skin lesions affect the fingers and the toes primarily and are referred to as digital purpura [ 29 ].…”

Section: Dermatitis Herpetiformismentioning

confidence: 99%

Skin Manifestations and Coeliac Disease in Paediatric Population

et al. 2021

View full text Add to dashboard Cite

Celiac disease (CD) is an immune-mediated enteropathy caused by gluten ingestion, affecting approximately 1% of the worldwide population. Extraintestinal symptoms may be present as the first signs of CD, years before the CD diagnosis is made. A great variety of extraintestinal manifestations may be associated with CD. Cutaneous manifestations represent the main extraintestinal manifestations, with dermatitis herpetiformis being the most common in patients with CD. In adults, it has been demonstrated that the role of a gluten-free diet is crucial not only for the recovery of signs and symptoms associated with CD but also for cutaneous manifestations, which often improve after gluten avoidance. In children with CD, the association with skin disorders is well documented regarding dermatitis herpetiformis, but studies considering other dermatological conditions, such as psoriasis and atopic dermatitis, are few. The prevalence and manifestations of dermatological disorders in celiac children are often different from those in adults, explaining the gap between these populations. In addition, the therapeutic role of a gluten-free diet in the improvement in skin alterations is not fully understood in children and in adult population except for dermatitis herpetiformis. Therefore, cutaneous CD symptoms need to be known and recognized by physicians despite their specialties to improve early CD diagnosis, which is critical for a better prognosis. This review describes the current scientific evidence on skin manifestations associated with CD in the pediatric population.

show abstract

Recurrent Digital Petechiae and Weight Loss in a Young Adult

Cited by 4 publications

References 3 publications

When Hepatitis B Virus Meets Interferons

When Hepatitis B Virus Meets Interferons

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Skin Manifestations and Coeliac Disease in Paediatric Population

Contact Info

Product

Resources

About